As a high-quality forestry product with excellent performance, particleboard is widely used in many fields and has great market potential. At present, it is a research difficulty to accurately identify small, fine and different shapes of defects on the whole particleboard through machine vision technology. The application of image super-resolution reconstruction technology on particleboard can improve the surface image quality of particleboard, which is conducive to the subsequent improvement of defect detection accuracy. In this study, super-resolution dense attention generative adversarial network (SRDAGAN) model was improved to solve the problem that super-resolution generative adversarial network (SRGAN) reconstructed image would produce artifacts and its performance needed to be improved. The Batch Normalization (BN) layer was removed, the convolutional block attention module (CBAM) was optimized to construct dense block, and the dense blocks were constructed by densely skip connection. Then, the corresponding 52400 image blocks with high resolution and low resolution were trained, verified and tested according to the ratio of 3:1:1. The model was comprehensively evaluated from the effect of image reconstruction and the two indexes of PSNR and SSIM. It was found that compared with BICUBIC and SRGAN, PSNR index of SRDAGAN increased by 4.88dB and 3.25dB respectively, and SSIM increased by 0.0507 and 0.1122 respectively. The reconstructed images not only had clearer texture, but also had more realistic expression of various features, and the performance of the model had been greatly improved. At the same time, this study also emphatically discussed on the image reconstruction effect with defects. The result showed that the SRDAGAN proposed in this study can complete the super-resolution reconstruction of particleboard images with high quality. In the future, it can also be further combined with defect detection for actual production to improve the quality of forestry products and increase economic benefits.

In kidney, epithelial barrier has diverse functions in body fluid and electrolyte homeostasis, and urine production. Maintaining epithelial integrity fundamentally builds up physiological functionality of the renal epithelial barrier (REB). Specially, the REB) states regularly in osmotic dynamics. The osmotic dynamics gives rise of osmotic pressure that is a physical force. Overloading of osmotic pressure can crack epithelial integrity and damage REB. How REB endures the osmotic pressure force yet remains enigmatic. LMO7 (LIM domain only 7) is a protein associated with cell-cell junctional complex and cortical F-actin. LMO7 upregulation was observed in cells cultured in hypertonic condition. In kidney, LMO7 predominantly distributes in epithelial cells in renal tubules. Hypertonic stimulation leads to assembly of LMO7 and F-actin in cortical stress fibers in renal epithelial cells. Hypertonic-isotonic alternation as pressure force pushing plasma membrane inward/outward was set as osmotic disturbance and was applied to test FAK signaling and LMO7 functioning in maintaining junctional integrity. Along with junctional integrity, LMO7 depleted cells resulted in loss of junctional integrity in the epithelial sheet cultured hypertonic medium or hypertonic-isotonic alternation. On the other hand, FAK inhibited by PF-573228 leads to failure in robust cortical F-actin assembly and association of LMO7 with cortical F-actin in epithelial cells responding upon hypertonic stress. Epithelial integrity in context of osmotic stress, LMO7 and FAK signaling both involves in assembling robust cortical F-actin and maintaining junctional integrity. The LMO7 elaborately manages FAK activation in renal epithelial cells, which was evidently demonstrated in NRK-52E cells who have excessive FAK activation and lost epithelial integrity when cells with LMO7 depletion exposed to hypertonic environment. Our data suggests that LOM7 manages FAK activation and is responsible for maintaining REB under osmotic disturbance.

Hepatic encephalopathy (HE) reduces survival in cirrhotic patients and correlates with systemic inflammation and gut-liver disequilibrium. We investigated the association between propranolol treatment and outcomes for cirrhotic patients with HE. Using data from the Taiwan National Health Insurance Research Database, we identified 4,754 cirrhotic patients newly diagnosed with HE. Among them, 519 patients received propranolol treatment and the other 519 patients without exposure to propranolol were enrolled into our study, both of which were matched by sex, age, and propensity score. The median overall survival (OS) was longer in the propranolol-treated cohort than in the untreated cohort (3.46 versus 1.88 years, p<0.001). A dose-dependent increase in survival was observed (median OS: 4.49, 3.29, and 2.46 years in patients treated with propranolol >30mg/day, 20–30mg/day, and <20mg/day, respectively [p<0.001, p=0.001, and p=0.079 versus the untreated group]). In addition to reduce the risk of mortality (adjusted hazard ratio, 0.58; p<0.001), propranolol also diminished the risk of sepsis-related death (adjusted hazard ratio, 0.31; p=0.006) according to the multivariate analysis. However, the risk of circulatory or hepatic failure was non-significantly altered by propranolol treatment. In conclusion, propranolol treatment was associated with a better OS in cirrhotic patients with HE and its effects were dose-dependent.